Johnson & Johnson CEO Alex Gorsky: 5 things to know on 2017

Johnson & Johnson’s CEO Alex Gorsky will make responsible drug pricing a priority in the coming year after meeting with President Donald Trump, according to a Yahoo Finance report.

Advertisement

Here are five key notes:

 

1. After the meeting, Mr. Gorsky said he would like to see changes to the U.S. tax code and healthcare policy.

 

2. Johnson & Johnson had a turbulent start to the year, with 2016 fourth quarter sales falling short of expectations.

 

3. Johnson & Johnson was the first major healthcare company to report sales after Mr. Trump criticized the high prices of medications. The company reported it would limit annual product price increases to single digits in percentage terms.

 

4. The company is planning to release a pharmaceutical transparency report and expand disclosures on U.S. pricing, research and development expenses.

 

5. Mr. Gorsky said the company will also disclose compassionate care programs.

 

More articles on orthopedic devices:
Zimmer Biomet, Implanet, Spinal Elements & more: 8 device company key notes
SpineFrontier improves MISquito Percutaneous Pedicle Screw System: 7 key points
Orthofix reports final resolution to SEC investigations: 6 insights

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new product launches and leadership appointments, here are seven key headlines from Stryker in the first quarter of 2026.…

  • Xtant Medical’s 2025 revenue reached $133.9 million, a 14% increase year over year, according to financial results posted March 31.…

Advertisement

Comments are closed.